Our institutional experience with high-grade pediatric spinal cord tumors includes 11 children treated during the period of 1981-1997. All patients underwent a biopsy or an attempt at resection and received postoperative radiation therapy. Three patients had a gross-total resection of their primary tumor, 6 patients had a subtotal resection and the remaining 2 were biopsied. Histologically, these tumors were characterized as anaplastic astrocytoma (n = 6), glioblastoma multiforme (n = 3) or anaplastic oligodendroglioma (n = 2). Three patients were treated with craniospinal irradiation (38-48 Gy) in addition to a boost to the residual tumor. The median dose to the primary site for all patients was 48.6 Gy (range 38-55 Gy). The median overall survival was 13 months (range 8-149 months). Only 2 patients were alive at 138 and 149 months following radiation therapy. The median progression-free survival following radiation therapy was 10 months (range 2-80 months). There was no difference in progression-free or overall survival for those diagnosed with glioblastoma multiforme when compared to patients diagnosed with anaplastic astrocytoma or anaplastic oligodendroglioma. The pattern of failure was either diffuse or local. For the patients who failed diffusely (n = 6), the median progression-free survival was 2 months compared to 23 months for those whose failure was entirely local (p < 0.01). The median overall survival was significantly shorter for those who failed diffusely compared to those who failed locally (10 vs. 37 months, p < 0.01). High-grade spinal cord tumors in children have a poor prognosis based on this report. It is important to document the extent of disease accurately prior to the initiation of radiation therapy, since a subset of these patients progress rapidly outside of the field of irradiation.

1.
Allen JC, Aviner S, Yates AJ, Boyett JM, Cherlow JM, Turski PA, Epstein F, Finlay JL: Treatment of high-grade spinal cord astrocytoma of childhood with ‘8-in-1’ chemotherapy and radiotherapy: A pilot study of CCG-945. J Neurosurg 1998;88:215–220.
2.
Constantini S, Houten J, Miller DC, Freed D, Ozek MM, Rorke LB, Allen JC, Epstein FJ: Intramedullary spinal cord tumors in children under the age of 3 years. J Neurosurg 1996;85:1036–1043.
3.
Kaplan ES, Meier P: Non-parametric estimations from incomplete observations. Am Stat Assoc J 1958;53:457–482.
4.
Norušis MJ: SPSS for Windows: Base System User’s Guide, release 6.0. Chicago, SPSS, 1993.
5.
Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al: Recursive partitioning analysis of prognostic factors in the Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–710.
6.
Jyothirmayi R, Madhavan J, Nair K, Rajan B: Conservative surgery and radiotherapy in the treatment of spinal cord astrocytoma. J Neurooncol 1997;33:205–211.
7.
McLaughlin MP, Marcus RB, Buatti JM, McCollough WM, Mickle JP, Kedar A, Maria BL, Million RR: Ependymoma: Results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998;40:845–850.
8.
Minehan KJ, Shaw EG, Scheithauer BW, Davis DL, Onofrio BM: Spinal cord astrocytoma: Pathological and treatment considerations. J Neurosurg 1995;83:590–595.
9.
Shirato H, Kamada T, Hida K, Koyanagi I, Iwasaki Y, Miyasaka K, Abe H: The role of radiotherapy in the management of spinal cord glioma. Int J Radiat Biol Oncol Phys 1995;33:323–328.
10.
Linstadt DE, Wara WM, Leibel SA, Gutin PH, Wilson CB, Sheline GE: Postoperative radiotherapy of primary spinal cord tumors. Int J Radiat Oncol Biol Phys 1989;16:1397–1403.
11.
Jain RK: The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 1998;4:655–657.
12.
Jain RK: 1995 Whitaker Lecture: Delivery of molecules, particles and cells to solid tumors. Ann Biomed Eng 1996;24:457–473.
13.
Smithers BM, Devitt P, Jamieson GG, Bassell J, Gothley D, Gill PG, Neely M, Joseph DJ, Yeoh EK, Burmeister B, Denham JW: A combined modality approach to the management of esophageal cancer. Eur J Surg Oncol 1997;23:219–223.
14.
Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Schwartz G, Saltz L, Dougherty J, Frankel J, Wiseberg J: Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1993;25:821–827.
15.
Gerbaulet AL, Kunkler IH, Kerr GR, Haie C, Michel G, Prade M, Lhomme C, Masselot M, Albano M, Dutreix A, Chassagne D: Combined radiotherapy and surgery: Local control and complications in early carcinoma of the uterine cervix – The Villejuif experience, 1975–1984. Radiother Oncol 1992;23:66–73.
16.
Colleoni M, Nole F, Minchella I, Noberasco C, Luini A, Orecchia A, Veronesi P, Zurrida S, Viale G, Goldhirsch A: Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer 1998;34:641–645.
17.
Deutsch MA, Leopold KA, Crawford J, Wolfe W, Foster W, Blackwell S, Yost R: Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. Cancer Treat Rev 1993;19:53–62.
18.
Tjho-Heslinga RE, Terhaard CH, Schouwenburg P, Hilgers FJ, Dolsma WV, Cross GA, Hoogenhout J, Knegt PP, Leer JW, Hordijk GJ: T3 laryngeal cancer, primary surgery vs planned combined radiotherapy and surgery. Clin Otolaryngol 1993;18:536–540.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.